Heron Therapeutics, Inc. (NASDAQ:HRTX) Short Interest Update

Heron Therapeutics, Inc. (NASDAQ:HRTX) was the target of a large decrease in short interest in the month of September. As of September 30th, there was short interest totalling 31,700,000 shares, a decrease of 10.6% from the September 15th total of 35,440,000 shares. Based on an average daily volume of 2,200,000 shares, the days-to-cover ratio is presently 14.4 days.

Heron Therapeutics Trading Down 2.9 %

HRTX traded down $0.06 during mid-day trading on Thursday, hitting $1.82. 158,247 shares of the stock were exchanged, compared to its average volume of 2,462,121. The firm’s fifty day moving average is $1.93 and its two-hundred day moving average is $2.66. Heron Therapeutics has a 1-year low of $0.50 and a 1-year high of $3.93. The company has a market cap of $273.44 million, a PE ratio of -3.07 and a beta of 1.80.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The company had revenue of $36.02 million during the quarter, compared to analysts’ expectations of $35.35 million. During the same quarter last year, the firm posted ($0.35) earnings per share. As a group, research analysts anticipate that Heron Therapeutics will post -0.1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reiterated a “buy” rating and set a $5.00 price target on shares of Heron Therapeutics in a report on Wednesday, September 25th.

Institutional Investors Weigh In On Heron Therapeutics

Hedge funds have recently bought and sold shares of the stock. nVerses Capital LLC acquired a new stake in Heron Therapeutics in the 2nd quarter valued at about $27,000. Headlands Technologies LLC acquired a new stake in shares of Heron Therapeutics during the 1st quarter worth about $30,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Heron Therapeutics during the 1st quarter worth about $32,000. HB Wealth Management LLC acquired a new stake in shares of Heron Therapeutics during the 2nd quarter worth about $35,000. Finally, B. Riley Wealth Advisors Inc. acquired a new stake in shares of Heron Therapeutics during the 2nd quarter worth about $41,000. Institutional investors and hedge funds own 80.01% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.